Treatment with Venetoclax Positively Modulates Immunological Parameters and T-Cell Features in Patients with Chronic Lymphocytic LeukemiaValentina Griggio, Marta Coscia, Francesca Perutelli et al.|Blood|2024Cited by 1
Venetoclax therapy in chronic lymphocytic leukaemia patients relapsed after allogeneic haematopoietic stem cell transplantationFrancesca Perutelli, Marta Coscia, Elia Boccellato et al.|British Journal of Haematology|2025Cited by 0
Targeting a novel surface antigen, ryk, with the antibody-drug conjugate, slv-404, is effective in richter transformation patient-derived xenograftsMatilde Micillo, Silvia Deaglio, Beatrice Pirajno et al.|Blood|2025Cited by 0
Venetoclax-based therapy remodels T-cell and NK-cell immunity in patients with chronic lymphocytic leukemiaGiorgia Mancin, Marta Coscia, Valentina Griggio et al.|Blood|2025Cited by 0
Absence of lymphocytosis after starting treatment with cbtki is a rare phenomenon except for CD49d positive CLL mainly expressed in trisomy 12.Luca Laurenti, Idanna Innocenti, Antonio Mosca et al.|Blood|2025Cited by 0